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Abstract
In the last several years, the use of dendritic cells has been studied as a therapeutic strategy against tumors. Dendritic cells 
can be pulsed with peptides or full-length protein, or they can be transfected with DNA or RNA. However, comparative studies 
suggest that transfecting dendritic cells with messenger RNA (mRNA) is superior to other antigen-loading techniques in gen-
erating immunocompetent dendritic cells. In the present study, we evaluated a new therapeutic strategy to fight tuberculosis 
using dendritic cells and macrophages transfected with Hsp65 mRNA. First, we demonstrated that antigen-presenting cells 
transfected with Hsp65 mRNA exhibit a higher level of expression of co-stimulatory molecules, suggesting that Hsp65 mRNA 
has immunostimulatory properties. We also demonstrated that spleen cells obtained from animals immunized with mock and 
Hsp65 mRNA-transfected dendritic cells were able to generate a mixed Th1/Th2 response with production not only of IFN-γ 
but also of IL-5 and IL-10. In contrast, cells recovered from mice immunized with Hsp65 mRNA-transfected macrophages were 
able to produce only IL-5. When mice were infected with Mycobacterium tuberculosis and treated with antigen-presenting cells 
transfected with Hsp65 mRNA (therapeutic immunization), we did not detect any decrease in the lung bacterial load or any 
preservation of the lung parenchyma, indicating the inability of transfected cells to confer curative effects against tuberculosis. 
In spite of the lack of therapeutic efficacy, this study reports for the first time the use of antigen-presenting cells transfected 
with mRNA in experimental tuberculosis.
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Tuberculosis (TB) is a major public health problem 
and remains one of the major causes of mortality from 
an infectious disease worldwide. About one-third of the 
world’s population has been infected with Mycobacterium 
tuberculosis. Today, the greatest difficulty in the treatment 
of TB is the necessity of continuous medication over a long 
period of time with multiple drugs (1). Most patients are 
averse or unable to complete a full course of medication, 
and patients who do not consistently undergo their therapies 
are at risk of relapsing and acquiring multidrug-resistant TB 
(1,2). Additionally, a sizable increase in the emergence of 
multidrug-resistant TB and the appearance of extremely 
drug-resistant TB, which is particularly dangerous for 
people with HIV/AIDS, has been found in all regions of 
the world. Thus, immunotherapy has been proposed as 
an alternative to treat TB, especially drug-sensitive TB. In 
addition, immunotherapy that enhances the efficiency of 
the immune response in M. tuberculosis-infected patients 
could be of additional value as a strategy to complement 
anti-bacterial chemotherapy. In the last decade, various 
nonspecific or antigen-specific immunological agents, such 
as DNA plasmids (3,4), cytokines (5), immunoglobulins (6), 
and mycobacterial antigens (7), have been used either 
alone or as adjuncts to chemotherapeutic regimens with 
varying success rates. 
Dendritic cells (DCs) are the most powerful antigen-
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presenting cells (APCs) that induce and maintain immune 
responses. These cells are notably efficient in the uptake 
and processing of antigen, express high levels of major 
histocompatibility complex class I and class II, as well as co-
stimulatory molecules, and migrate from the site of antigen 
uptake toward the lymph node, where they present major his-
tocompatibility complex (MHC) class I- and class II-restricted 
peptides to prime naive T cells (8). The combination of these 
properties makes DCs particularly suitable as vehicles for 
antigen presentation in immunotherapy. DC-based vaccines 
have therapeutic potential against tumors as demonstrated 
in murine models and several human clinical trials (9,10). 
DCs can be pulsed with a synthetic peptide (11) or full-length 
protein (12), transfected with DNA or RNA (13,14) or trans-
duced with recombinant viruses (15). However, comparative 
studies suggest that messenger RNA (mRNA) transfection 
is superior to other antigen-loading techniques in generating 
immunocompetent DCs (16,17). In addition to DCs, several 
studies also mention the use of macrophages as alternative 
vehicles for antigen presentation (18,19). 
Experimental data collected over the last few years have 
shown that a DNA vaccine encoding the M. leprae 65-kDa 
heat shock protein (DNA-Hsp65) has prophylactic and thera-
peutic efficacy in a murine model of TB (4,20). The therapeutic 
effect of this vaccine was associated with the presence of 
CD8+/CD44hi IFN-γ-producing cytotoxic cells (21,22). In 
addition, it was demonstrated that the DNA-Hsp65 vaccine 
could be taken up by CD11b+ (macrophages) and CD11c+ 
(DCs) cells after its administration in mice (23).
Based on the results obtained from studies with DNA-
Hsp65 and on recent data about the use of mRNA-loaded 
DCs in cancer treatment, we examined the therapeutic effect 
of immunizing TB-infected mice with DCs and macrophages 
transfected with Hsp65 mRNA. DCs generated from murine 
bone marrow cells and macrophages obtained from a peri-
toneal lavage were transfected with Hsp65 mRNA using 
electroporation or passive pulsing. We demonstrated that 
the therapeutic immunization with Hsp65 mRNA-transfected 
DCs or macrophages was not able to reduce the bacterial 
load in the lungs of infected animals. The mice received two 
doses of transfected cells intravenously or subcutaneously, 
and neither strategy was efficient in inducing therapeutic 
effects against TB. Additionally, the production of cytokines 
in the lung and the histopathology of infected mice were not 
altered by the immunization with transfected cells. In spite of 
the lack of therapeutic effects, this study represents the first 
time that APCs transfected with mRNA were used during an 
infection with M. tuberculosis. 
Material and Methods
Ethics statement
BALB/c (WT) mice, 6- to 8-week-old males, were pur-
chased from the Central Animal House of the Ribeirão Preto 
Campus, USP. The mice were maintained under standard 
conditions in the Animal House of the Departamento de 
Imunologia, Faculdade de Medicina de Ribeirão Preto, USP, 
Ribeirão Preto, SP, Brazil. All experiments with animals were 
approved and conducted in accordance with the guidelines 
of the Animal Care Committee of Faculdade de Medicina de 
Ribeirão Preto, USP (No. 053/2006).
Plasmid and in vitro transcription of Hsp65 mRNA
The pcDNA3A-Hsp65 construct was derived from the 
pcDNA3 vector (Invitrogen, USA). The vector was previously 
digested with BamHI and ApaI (Invitrogen), and a 1.8-kb frag-
ment corresponding to the M. leprae Hsp65 gene was inserted. 
For in vitro transcription, the pcDNA3A-Hsp65 plasmid was 
linearized with ApaI, and synthetic Hsp65 mRNA was generated 
using the mMESSAGE mMACHINE® T7 Ultra Reaction system 
(Ambion, USA) according to manufacturer recommendations. 
The concentration and quality of the pcDNA3A-Hsp65 plasmid 
and the Hsp65 mRNA were assessed by spectrophotometry 
and agarose gel electrophoresis.
DC generation from bone marrow
Murine DCs were generated according to the protocol 
described by Lutz et al. (24), with some modifications. Briefly, 
bone marrow cells prepared from the femora and tibiae of 
naive BALB/c mice were depleted of red blood cells with AcK 
lysis buffer (150 mM NH4Cl, 10 mM KCO3, 0.1 mM EDTA, 
pH 7.3) and cultured in RPMI 1640 medium (Gibco-BRL, 
USA) supplemented with 10% fetal bovine serum (Gibco-
BRL), 100 mM Na pyruvate, 100 mM non-essential amino 
acids, 200 mM L-glutamine, 100 IU/mL penicillin, 100 µg/mL 
streptomycin, 10 µg/mL gentamycin, 10 mM 2-ME, 10 ng/mL 
murine GM-CSF (BD Biosciences, USA) and 5 ng/mL murine 
IL-4 (BD Biosciences) at 37°C and 5% CO2. On day 3, the 
non-adherent granulocytes and T and B cells were gently 
removed, and fresh DC medium was added. On days 5, 7, and 
9, 80% of the medium was replaced with fresh DC medium. 
On day 10, non-adherent cells were harvested for phenotypic 
analysis (flow cytometry) and mRNA transfection. 
Transfection of DCs and macrophages
The mRNA transfection of DCs (from the bone marrow) 
and peritoneal macrophages (obtained from a peritoneal 
lavage with cool PBS) was performed by electroporation (for 
intravenous immunization) or passive pulsing (for subcutane-
ous immunization). For electroporation, immediately before 
transfection, DCs and macrophages were washed twice in 
PBS, pH 7.2, and the cells (1 x 106 cells) were resuspended 
in 400 µL Opti-MEM (Gibco-BRL). The cells were mixed with 
5 µg mRNA in a 0.4-cm sterile disposable electroporation 
cuvette and transfected in a Gene Pulser Xcell™ (Bio-Rad, 
USA) with a voltage pulse of 300 V in combination with 
a capacitance of 150 µF. After electroporation, the cells 
were immediately resuspended in RPMI 1640 medium and 
further incubated for 1 h at 37°C and 5% CO2. For contact 
transfection, the cells were incubated with 5 µg mRNA for 
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1 h in Opti-MEM (Gibco-BRL) at 37°C and 5% CO2. These 
transfected cells were used for in vitro flow cytometry analysis 
and in vivo immunization. 
Flow cytometry analysis
Dendritic cells derived from the differentiation of bone 
marrow cells and macrophages obtained from peritoneal 
lavage were pre-incubated with 2.4 G2 monoclonal antibod-
ies (mAb) to block FcγR (Pharmingen, USA) and were then 
incubated with the relevant mAb for 30 min at 4°C. DCs were 
labeled with anti-CD11c-FITC (clone HL3), and macrophages 
were stained with anti-CD11b-FITC. A biparametric gate was 
drawn around the cell population in the forward and side 
scatter dot plot. The gated populations were subsequently 
selected according to CD11b+ or CD11c+ staining. Anti-
CD80, anti-CD86, anti-CD40, and anti-IAd (MHC II) were used 
as phycoerythrin-conjugates (all antibodies were purchased 
from Pharmingen). Analytical flow cytometry was carried out 
using a FACScan instrument (Becton Dickinson, USA), and 
the data were processed using the WinMDI software. 
Animals and immunization procedures
Female 8-week-old BALB/c mice were obtained from 
the animal facility at Faculdade de Medicina de Ribeirão 
Preto, USP. Infected animals were kept in the biohazard 
facility at Laboratory Biosafety Level 3 and were housed in 
cages within a laminar flow safety enclosure under standard 
conditions. For the immunogenicity assay, mice were intra-
venously injected in the retro-orbital venous sinus with one 
dose of Hsp65 mRNA transfected DCs (DCs/Hsp65 mRNA, 
1 x 106 cells/dose), Hsp65 mRNA transfected macrophages 
(macrophages/Hsp65 mRNA, 1 x 106 cells/dose), DCs only 
(mock DCs, 1 x 106 cells/dose), or macrophages only (mock 
macrophages, 1 x 106 cells/dose). For the BCG immuniza-
tion, one dose of the Moreau strain was delivered in the 
dorsum by the subcutaneous injection of 105 live bacteria 
in 100 µL saline. For the therapeutic immunization assays, 
mice were injected intravenously in the retro-orbital venous 
sinus or subcutaneously in the dorsum with two doses (at 
2-week intervals) of DC/Hsp65 mRNA (1 x 106 cells/dose), 
macrophages/Hsp65 mRNA (1 x 106 cells/dose), mock DCs 
(1 x 106 cells/dose), or mock macrophages (1 x 106 cells/
dose). The immunogenicity and therapeutic immunization 
assays were performed using 5 animals per group.
Proliferation assay
Splenocytes were isolated from the immunized mice 
(immunogenicity assay) and labeled with CFSE (Invitrogen). 
The 5 mM stock solution of CFSE was diluted to 5 µM in a 
volume of PBS equal to the volume in which spleen cells (2.5 
x 106/400 µL) were suspended, and the cells were subse-
quently incubated at 37°C for 5 min. The labeling process was 
quenched by adding 1/20 of the volume of heat-inactivated 
fetal bovine serum (FBS) (Gibco-BRL) to the sample. After 
1 min, CFSE-labeled cells were washed twice, recounted, 
and adjusted to a concentration of 2.5 x 106 cells/mL in RPMI 
1640 culture medium (Gibco-BRL), which contained 10% 
FBS (Gibco-BRL), gentamycin, and penicillin/streptomycin. 
Next, the cells were plated onto 48-well tissue culture plates 
(2.5 x 106 cells/well). The cells were stimulated with 10 µg 
BCG or 20 µg Hsp65 recombinant protein plus 30 µg/mL 
Polymixin B (Sigma, USA) for 72 h at 37°C and 5% CO2. 
Negative and positive controls were performed using spleen 
cells cultured in the presence of culture medium only or with 
20 µg concanavalin A (Sigma), respectively. The cells were 
harvested and analyzed by flow cytometry.
Cytokine evaluation
For the immunogenicity assay, splenocytes from mice 
killed 15 days after immunization were purified by lysing the 
erythrocytes. The cells (2.5 x 106) were stimulated in vitro 
with 10 µg/mL Hsp65 recombinant protein or with 20 µg/mL 
concanavalin A. A negative control was performed using 
spleen cells cultured at 37°C and 5% CO2 in the presence 
of complete medium (RPMI-1640, Gibco-BRL) containing 
10% FBS (Gibco-BRL), gentamicin, and penicillin/strepto-
mycin. The level of cytokines in the culture supernatant was 
evaluated 48 h later. Supernatants were stored at -20°C. For 
cytokine measurements of the lung, the entire left lobe of the 
lung was removed 30 days after therapeutic immunization 
with the transfected cells. The tissue was homogenized in 2 
mL RPMI 1640 and centrifuged at 450 g, and the superna-
tant was stored at -70°C. The levels of the cytokines IFN-γ, 
IL-12, IL-5, and IL-10 were determined in the spleen cell 
supernatants, and IFN-γ and IL-12 were measured in the left 
lung lobe homogenates by ELISA according to manufacturer 
instructions. The capture antibodies and biotinylated mono-
clonal antibodies for IFN-γ (R4-6A2, XMG1.2), IL-12 (C15.6, 
C17.8), IL-5 (TRKF5, TRFK4), and IL-10 (JES5-2A5, SXC-1) 
as well as the recombinant cytokines, were purchased from 
Pharmingen.
Experimental infection with M. tuberculosis
The H37Rv M. tuberculosis strain (American Type Cul-
ture Collection 27294, USA) was grown in 7H9 Middlebrook 
Broth (Difco Laboratories, USA) for 7 days. The culture was 
harvested by centrifugation and the cell pellet was then re-
suspended in sterile PBS and vigorously shaken with glass 
spheres. The viability of the bacteria in suspension was 
evaluated using fluorescein diacetate (Sigma) and ethidium 
bromide. For the therapeutic immunization assays, the mice 
were first infected by the intranasal route with 105 viable 
colony-forming units (CFU) of M. tuberculosis H37Rv in 100 
µL PBS. Thirty days after M. tuberculosis infection, the mice 
were treated with the transfected cells. Fifteen days after 
treatment, the mice from all groups were euthanized.
Determination of M. tuberculosis CFU in lungs 
The determination of M. tuberculosis CFU was performed 
as described previously (4). Briefly, the number of live bacteria 
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was determined by extracting the lower and medium right 
lobes of the lung, washing the lobes with sterile PBS, and 
subsequently plating 10-fold serial dilutions of the homog-
enized tissue onto Middlebrook 7H11 agar medium (Difco) 
supplemented with 0.2% (v/v) glycerol and 10% (v/v) FBS. 
Next, the colonies were counted after culturing for 28 days 
at 37°C. The CFU are reported as log10 CFU/g lung.
Histology
Fifteen days after the therapeutic immunization, the 
upper right lobes of the lungs were fixed in 10% forma-
lin, embedded in paraffin blocks, prepared routinely, and 
subsequently sectioned for light microscopy. For the his-
topathological analyses, sections (5 µm) were stained with 
hematoxylin and eosin. The slides were evaluated using a 
Leitz Model Aristoplan microscope (Germany) connected 
to a Leica Model DFC280 color camera (Germany) linked 
to a PC computer. To perform a morphometric analysis of 
the lung parenchyma, an integrating eyepiece with a coher-
ent system made of a 100-point grid consisting of 50 lines 
of known length was coupled to the slides and evaluated 
by light microscopy. The fractions of collapsed and normal 
pulmonary areas were determined by the point-counting 
technique at a magnification of 400X across 10 random, 
non-coincident microscopic fields. The points falling on a 
tissue area were counted and divided by the total number of 
points in each microscopic field. Thus, the data are reported 
as the fractional area of pulmonary tissue.
Statistical analysis
Data are reported as means ± SD and were analyzed 
using GraphPad Prism version 5.0 for Windows (GraphPad 
Software, USA). The significance of the difference among 
groups was calculated by ANOVA followed by the Tukey 
multiple comparison test. Values of P < 0.05 were consid-
ered to be significant.
Results
Phenotype of macrophages and dendritic cells 
transfected in vitro with Hsp65 mRNA
For the phenotypic characterization of the APCs that 
were pulsed with Hsp65 mRNA, electroporated cells (mock) 
or APCs that were electroporated with Hsp65 mRNA, we 
evaluated the expression of cell surface markers. Untreated 
APCs or cells treated with lipopolysaccharide were used 
for negative and positive controls, respectively (Figure 1D 
and H). Twenty-four hours after the stimuli, the expres-
sion of CD80, CD86, CD40, and MHC class II (MHC-II) 
was analyzed. The analysis of the histograms in Figure 1 
reveals a different expression profile of surface molecules 
between the macrophages and DCs. This difference is 
most evident in the histograms representing the expres-
sion of MHC-II; the macrophages obtained from the peri-
toneal lavage express higher levels of MHC-II compared 
to DCs differentiated from bone marrow cells. In addition, 
the expression profile of MHC-II barely changes when the 
cells are transfected (pulsed or electroporated) with Hsp65 
mRNA for both APC populations. Macrophages pulsed with 
mRNA, electroporated only (mock) and electroporated with 
mRNA showed increased expression of CD80, CD40 and 
especially CD86 (Figure 1A-C). The surface expression 
pattern of the DCs is represented in Figure 1E-G. The cells 
transfected with Hsp65 mRNA (pulsed or electroporated) 
showed an up-regulation of CD80, CD86, and CD40. The 
mock transfected DCs had a slightly increased expression 
of CD86 and CD40. Taken together, these results indicate 
that macrophages and also DCs acquired surface markers, 
specifically CD86, of partially mature APCs when submitted 
to Hsp65 mRNA transfection. Additionally, in our analysis, 
the process of electroporation caused an increase in the 
expression of some co-stimulatory molecules on mac-
rophages and DCs (Figure 1B and F). Moreover, Hsp65 
mRNA also showed to some extent the ability to induce the 
maturation of APCs. 
The percentage of CD11c+ cells (derived from the 
differentiation of bone marrow cells) was always checked 
and an average of 72% (72.03 ± 7.8) of the cells showed 
positive labeling. The remaining cells in the culture were 
CD11b+. The viability of APCs following transfection (elec-
troporation) was 80 to 90% (data not shown), quite similar 
to the viability of the cells prior to transfection. Viability was 
checked with Trypan blue.
Immune responses induced by immunization with 
Hsp65 mRNA-transfected macrophages or Hsp65 
mRNA-transfected DCs
For the immunogenicity assay, mice received one 
dose of Hsp65 mRNA-electroporated DCs (DC/Hsp65 
mRNA, 1 x 106 cells/dose), Hsp65 mRNA-electroporated 
macrophages (macrophages/Hsp65 mRNA, 1 x 106 cells/
dose), electroporated DCs (mock DCs, 1 x 106 cells/dose), 
or electroporated macrophages (mock macrophages, 1 x 
106 cells/dose) by intravenous injection. The control groups 
were immunized subcutaneously with BCG or intravenously 
with saline. Fifteen days after immunization, the animals 
were sacrificed, and cell proliferation and cytokine produc-
tion were evaluated after in vitro stimulation of the spleen 
cells with recombinant Hsp65 protein or BCG lysate. When 
we assessed the lymphoproliferation induced in the spleen 
cells recovered from the immunized animals, only the sple-
nocytes derived from mice immunized with Hsp65 mRNA-
transfected DCs induced T-cell proliferation. Moreover, the 
proliferative capacity of T cells did not depend on secondary 
stimulation with the Hsp65 antigen in vitro (Figure 2). This 
result suggests that the DCs that developed in this system 
are capable of activating T cells in vivo following adoptive 
transfer but that the response seems to have multiple 
specificities. It is probable that during the in vitro culture, 
the exposure of DCs to the foreign proteins contained in 
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Figure 1. The phenotype of macrophages (A-D) and dendritic cells (E-H) transfected in vitro with Hsp65 mRNA. Macrophages and 
dendritic cells (DCs) were transfected by contact with Hsp65 mRNA (A and E), electroporated (B and F), electroporated with 5 µg Hsp65 
mRNA (C and G) or stimulated with lipopolysaccharide (LPS; D and H). The phenotype of the cells was analyzed by flow cytometry, and 
the histograms show the expression of the CD80, CD86, CD40, and MHC-II molecules. The gray lines show cells that were not stimulated, 
and the black lines show stimulated cells. Data are representative of 3 experiments yielding similar results. Mφ = macrophages.
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FBS, combined with the fact that the proliferation assay 
was conducted in the presence of FBS, was responsible for 
the T-cell proliferation. The splenocytes isolated from mice 
immunized with Hsp65 mRNA-transfected macrophages 
were not able to proliferate in vitro (Figure 2). The cytokine 
assays revealed that spleen cells recovered from both 
mock and Hsp65 mRNA-transfected DC-immunized mice 
produced high levels of IFN-γ, IL-10 and IL-5 (Figure 3B-
D). It is probable that cytokine production occurred due to 
the expression of co-stimulatory molecules (Figure 1). The 
cells recovered from mice immunized with Hsp65 mRNA-
transfected macrophages were able to produce only IL-5 
(Figure 3D). We hypothesized that this result might be an 
intrinsic characteristic of the immune response induced by 
this type of APC. Although only IL-12 production could be 
detected from the cells recovered from the animals vac-
cinated with BCG, we believe that IFN-γ production can be 
attributed to an indirect action of other cells in vivo, such 
as natural killer cells (Figure 3A). The analysis of cytokine 
production induced by immunization with DCs reflects the 
ability of this subtype of professional APC to be potentially 
capable of inducing a mixed Th1/Th2 profile with high 
levels of IFN-γ, as well as IL-5 and IL-10. In contrast, the 
immunization with macrophages seemed to evoke only a 
Th2 response. 
Mice infected with M. tuberculosis and treated with 
Hsp65 mRNA-transfected APCs 
For the therapy tests, BALB/c mice were infected intra-
nasally with 1 x 105 bacilli from the H37Rv virulent strain of 
M. tuberculosis. Thirty days after infection, the mice were 
treated with 2 doses of different APC formulations: mock 
macrophages, mock DCs, macrophage/Hsp65 mRNA, or 
DC/Hsp65 mRNA by intravenous or subcutaneous injection 
(therapeutic immunization). Fifteen days after the second 
dose of transfected cells, the lungs were extracted, and the 
therapeutic effect was evaluated according to the number of 
CFU, lung tissue preservation and cytokine production. 
First, we evaluated the number of bacteria in the lungs 
of infected and treated mice, and no therapeutic effect 
was detected (Figure 4A). A change in the immunization 
route also did not reduce bacterial loads (Figure 4B). The 
preservation of the lung parenchyma, in addition to a re-
duction of CFU, is essential to assess the effectiveness 
of new treatments against TB. Thus, the lungs of infected 
and treated animals were collected and submitted to histo-
Figure 2. Evaluation of Hsp65-specific immune responses by immunization with Hsp65 mRNA-trans-
fected macrophages or Hsp65 mRNA-transfected dendritic cells (DCs). Mice were immunized (one 
dose, intravenous) as described in Material and Methods (Immunogenicity assay section). Fifteen 
days after immunization, the splenocytes were collected for proliferation assays. Data are reported 
as means ± SD of 5 mice. Results are representative of 2 experiments. *P < 0.05 versus the non-
immunized group, medium/BCG, mock macrophage group, macrophage/Hsp65 mRNA group, and 
mock DC group; #P < 0.05 versus the non-immunized group, medium/BCG, mock macrophage group, 
stimulated-macrophage/Hsp65 mRNA group, and mock DC group (ANOVA followed by the Tukey 
multiple comparison test). Mφ = macrophages.
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Figure 3. Cytokine production by spleen cells from immunized mice. Mice were immunized as described in Material 
and Methods (Immunogenicity assay section). Fifteen days after immunization, the production of IL-12 (A), IFN-γ 
(B), IL-10 (C), and IL-5 (D) by spleen cells cultured with Hsp65 (10 µg/mL), BCG (10 µg/mL) or concanavalin A 
(20 µg/mL) was evaluated. Data are reported as means ± SD absorbance of 5 mice. Each result is representative 
of 2 experiments. A, *P < 0.05 versus the medium-BCG and other groups; B, #P < 0.05 versus the medium-BCG 
and other groups; ‡P < 0.05 versus the non-immunized group, medium-BCG, mock macrophage group, medium-
macrophage/Hsp65 mRNA; †P < 0.05 versus the non-immunized group, medium-BCG, mock macrophage group, 
macrophage/Hsp65 mRNA group; C, *P < 0.05 versus the non-immunized group, medium-BCG, mock macrophage 
group, macrophage/Hsp65 mRNA group; #P < 0.05 versus the other groups; D, *P < 0.05 versus the non-immu-
nized group; †P < 0.05 versus the non-immunized group; #P < 0.05 versus the other groups (ANOVA followed by 
the Tukey multiple comparison test). Mφ = macrophages; DC = dendritic cells.
Figure 4. Calculation of the numbers of Mycobacterium tuberculosis in the lungs from 
BALB/c mice immunized by intravenous (A) or subcutaneous (B) injection. Mice were 
infected with M. tuberculosis and treated with transfected cells as described in Material 
and Methods. Data are reported as log10 of the number of colony-forming units (CFU)/g 
per lung obtained from means ± SD of the serial dilutions individually counted for each 
group. Results are representative of 2 experiments. Mφ = macrophages; DC = dendritic 
cells.
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pathological (Figure 5) and morphometric analysis (Figure 
6). As shown in Figure 5 (B-F,H-M), the lungs revealed a 
tuberculous pneumonia with a milder impairment of tissue 
parenchyma that showed an intense inflammatory infiltrate 
characterized by the presence of mononuclear cells and 
of bronchus-associated lymphoid tissue. There were also 
Figure 5. Histological representation of the lungs of mice immunized by intravenous (A-F) or subcutaneous (G-M) injec-
tion. Mice were infected with Mycobacterium tuberculosis and treated with transfected cells as described in Material and 
Methods. Lung sections from normal lung (control, A and G), non-immunized and infected mice (saline group, B and H), 
mock macrophage-immunized mice (C and I), macrophage/Hsp65 mRNA-immunized mice (D and J), mock dendritic cell 
(DC)-immunized mice (E and L), and DC/Hsp65 mRNA-immunized mice (F and M) are shown. Representative sections of 
HE staining are shown. Mφ = macrophages.
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numerous xantomatous mac-
rophages, which suggested 
the presence of bacilli. No dif-
ferences were found between 
the saline group (Figure 5B and 
H) and the other experimental 
groups (Figure 5C-F,I-M). The 
noninfected groups correspond 
to the normal lung tissue (Fig-
ure 5A and G). Morphometric 
analysis indicated that there 
was partial damage to the lung 
with 40% of the tissue area 
inflamed, but there were no dif-
ferences between the various 
experimental groups (Figure 
6A and B). No differences were 
found in the histopathological 
(Figure 5 H-M) and morphomet-
ric analysis (Figure 6B) between 
the experimental groups and 
the respective infected and 
untreated control group when 
the cells were administered by 
the subcutaneous route. Finally, 
when we assessed the cytokine 
levels directly from the lung 
homogenate from infected and 
treated animals (Figure 7A-D), 
no significant differences were 
found in the IL-12 and IFN-γ 
levels between the experimental 
groups (mock macrophages, 
mock DCs, macrophage/Hsp65 
mRNA, or DC/Hsp65 mRNA) 
and the saline groups irrespec-
tive of whether the immunization 
route was intravenous (Figure 
7A and B) or subcutaneous 
(Figure 7C and D).
Discussion
In the present study, we 
assessed the ability of mac-
rophages and DCs transfected 
with the messenger RNA of the 
Hsp65 protein from M. leprae 
to induce an immune response 
and to exert a therapeutic effect 
against M. tuberculosis infection 
in an adoptive transfer system. 
Our results showed that immunization with APCs transfected 
with Hsp65 mRNA presented no curative effects against TB 
infection because we could not detect any decrease in lung 
bacterial load or the preservation of the lung parenchyma 
in infected mice. 
Effective antimycobacterial immunity is presumed to 
Figure 6. Morphometric analysis of lung parenchyma from BALB/c mice immunized by intra-
venous (A) or subcutaneous (B) injection. Mice were infected with Mycobacterium tuberculo-
sis and treated with transfected cells as described in Material and Methods. We performed 
morphometric analysis of lung histology sections. Data represent means ± SD percent of the 
pulmonary area affected by inflammation of 5 mice per group. Results are representative of 2 
experiments. Mφ = macrophages.
Figure 7. Cytokine detection in the lungs of BALB/c mice immunized by intravenous (A and B) 
or subcutaneous (C and D) injection. Mice were infected with Mycobacterium tuberculosis and 
treated with transfected cells as described in Material and Methods. Local cytokine production 
was evaluated ex vivo in the lung homogenates. Data are reported as means ± SD absorbance 
of 5 mice. The results are representative of 2 experiments. Mφ = macrophages; DC = dendritic 
cells.
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be due to a Th1 response, which is dominated by antigen-
specific T lymphocytes that produce IFN-γ and are cytotoxic 
to infected cells (22,25). A Th2 response is characterized by 
IL-4 production, which is predominant during an infection 
with M. tuberculosis; Th2 responses have been reported to 
be non-protective in TB (22,26,27). A shift in the balance to-
ward a Th1 response may be beneficial, providing a criterion 
for the selection of protective antigens against tuberculosis. 
The Hsp65 antigen has been shown to be effective in treat-
ing TB when administrated as a DNA plasmid, and its effect 
was related to the CD8+/CD44hi IFN-γ-producing cytotoxic 
cells (21,22). Moreover, it has been demonstrated that one 
10-μg dose of naked mRNA encoding Hsp65 was enough 
to protect mice from M. tuberculosis infection. It was also 
demonstrated that this naked Hsp65 mRNA could stimu-
late Th1-specific cytokine production. In addition, Western 
blot analysis confirmed the mRNA Hsp65 stability and the 
Hsp65 protein expression in transfected cells at various time 
points after the mRNA uptake (28). However, our approach, 
which used the same antigen in a different formulation 
(using APCs as vehicles for Hsp65 mRNA transference), 
did not show the same therapeutic effects. We believe 
that the failure of this new model lies either in the inability 
of transfected APCs to promote a shift to a protective Th1 
response or in the fact that transfected APCs may create 
a modulation of the immune response. In agreement with 
this hypothesis, DC-activated T cells proliferated vigorously 
in vitro without obvious signs of antigenic specificity upon 
adoptive transfer into naive recipients (Figure 2). When we 
assessed the cytokine production, we observed a similar 
result from cells recovered from mice immunized with 
transfected DCs (Figure 3). We speculate that the same 
effect could not be observed from cells harvested from 
macrophage-immunized mice due to the intrinsic properties 
of these APCs in our experimental model. In fact, the low 
effectiveness of macrophages when compared with DCs 
in an APC-based immunization model has already been 
reported (19). Another explanation is based on nonspecific 
T-cell activation due to bystander effects provided by APCs 
stimulated via cytokine networks. As shown in Figure 3, 
DCs and, to a lesser extent, macrophages produced sig-
nificant quantities of different cytokines in vitro. It has been 
demonstrated that, following the vaccination of mice with 
exogenous DCs, the animal’s endogenous DCs can activate 
T-cells in a bystander nonspecific manner (29). Moreover, 
in a study with cancer patients, it has been demonstrated 
that T-cell reactivity to a mock DC immunization reflects a 
possible T-cell stimulation through co-stimulatory molecules 
and cytokines (30). The analysis of cytokine production 
induced by immunization with DCs reflects the ability of 
this subtype of APCs to be potentially capable of inducing 
a mixed Th1/Th2 response with high levels of IFN-γ, as 
well as of IL-5 and IL-10 (Figure 3). This phenomenon may 
have direct implications for a therapeutic approach because 
protective effects against TB are strongly associated with 
a predominantly Th1 response. 
Independent of the mechanism of action of the mock 
cells, we believe that there are details concerning the im-
munization protocols that should be considered. Another 
possibility that could explain the absence of therapeutic 
effects in our model might be related to the maturation 
status of APCs. Immature DCs might not be ignored by the 
immune system but might instead lead to tolerance (31,32). 
Moreover, the type of stimulatory signals that DCs and 
possibly other APCs emit could also be a critical factor for 
the induction of a protective response. In an experimental 
model of leishmaniasis, DCs pulsed with antigens from 
Leishmania major were observed to be activated with 
CpG oligonucleotides (CPG ODN), TNF-α or anti-CD40 
Ab, but only those treated with CPG ODN were able to 
induce protection. This phenomenon was associated with 
the induction of a potent Th1 response in vivo (33). Other 
models draw attention to the degree of activation of these 
APCs. A specific case report showed that the incomplete 
activation of the DCs in a standard immunization against 
leishmaniasis led to an undesirable Th2 response, resulting 
in lack of protection (34). In contrast, there are also cases in 
which a protective response is observed even in the absence 
of DC stimulation prior to immunization (35). Curiously, in 
an experimental model against TB, immunization with a 
DC-pulsed peptide was able to induce protection without 
any requirement for DC activation (36).
Another element that seems to be involved in the gen-
eration of protection in DC-based vaccines is the route of 
administration. Although it was demonstrated that antigen-
loaded DCs may prime the T-cell response regardless of 
the route of injection, the quality of the response may be 
affected. An intravenous immunization seems to favor the 
migration of DCs initially to the lung with subsequent ac-
cumulation in the spleen. In contrast, after subcutaneous 
administration, DCs preferentially accumulate in the T-cell 
areas of the draining lymph nodes (37). Regardless of the 
information provided by those studies, a standard protocol 
of the proper inoculation route has yet to be established. 
In the present study, we tested the effectiveness of two 
immunization routes, i.e., intravenous and subcutaneous 
and we did not find any differences between these two 
strategies. 
The attempt to induce protection by transferring DC-
pulsed peptides or proteins from M. tuberculosis has been 
described in some experimental models with diverse re-
sults. Some studies have shown a protective ability of DCs 
infected with BCG or M. tuberculosis. In these models, it 
is clear that the pathogens have the ability to promote the 
maturation of DCs and that DCs are important in protecting 
against the disease. Moreover, this effect was linked to the 
induction of a strong T-cell response with the production 
of IFN-γ (38). However, variability between these models, 
such as differences in the infection model and the im-
munization route, make it difficult to establish clearly the 
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parameters that led to the protection. Studies performed 
by other groups also obtained protection when DCs were 
pulsed with M. tuberculosis peptides; again, the results 
were quite variable with differences in the necessity for 
the maturation of DCs, the number of doses, the amount 
of transferred cells, and the route of immunization (36,39). 
In contrast, other immunization studies with DCs were not 
able to induce protection against TB. Rubakova et al. (35), 
in addition to showing the influence of FBS, noted a lack 
of protection with intravenous immunization. Furthermore, 
a lack of protection was also observed in conjunction with 
increased inflammation of the lung parenchyma when DCs 
pulsed with Ag85 from M. tuberculosis were administered 
by the intranasal route (40). 
It is evident from the results reported here that further 
manipulation of APCs might be required to regulate their 
capacity to trigger Th1-like immunological properties in 
vivo to achieve an optimal outcome of immunization. Ad-
ditionally, manipulations of the mRNA sequences may be 
useful to increase antigen expression and to contribute 
to the induction of a robust effector and memory immune 
response. Moreover, the data presented in this study pri-
marily reflect the difficulty of inducing protection against 
M. tuberculosis and raise questions concerning the best 
parameters to generate an effective response in an APC-
based immunization. 
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